Treatment Of SKBR3 (HER2+) Breast Cancer Cells with Neuregulin 1 Increases Cell Proliferation and Migration, and Completely or Partially Impairs the Efficacy of Anti-ERBB2 Targeting Drugs Trastuzumab and Pertuzumab. Here, ERBB2 is linked to breast carcinoma.